Introduction {#sec1}
============

The extrinsic pathway initiates thrombin formation at injured regions, whereas the intrinsic pathway mediates continuous thrombin production and fibrin clot generation to stabilize a thrombus. Factor XII (FXII) is the initiator of the intrinsic pathway and is analogous to fibrinolytic proteins; FXII can be activated to form FXIIa via contact with negatively charged substances, such as polyphosphates,[@bib1] nucleic acids,[@bib2], [@bib3] protein aggregates,[@bib4] and collagen.[@bib5] Once activated, FXIIa immediately catalyzes FXII and prekallikrein (PK) to trigger the intrinsic pathway and the kallikrein kinin system (KKS),[@bib6] which are closely related to coagulation and inflammatory responses.[@bib7]

FXII can effectively start the intrinsic coagulation pathway but is nonessential for hemostasis.[@bib8] Previous research showed that FXII deficiency in humans and animals often occurs asymptomatically, and the depletion of plasma FXII can protect animals from thrombosis in various models.[@bib9] Therefore, new methods have been applied to inhibit FXII and prevent thrombus formation. For example, antisense oligonucleotide,[@bib10], [@bib11] RNA aptamer,[@bib12] and antibodies[@bib13] can efficiently suppress FXII expression and thrombosis *in vitro* or *in vivo*. However, none of these approaches can maintain a stable inhibitory effect without repeated injections.[@bib14]

RNAi has been widely used to silence genes by regulating the expression of specific mRNA. Compared with chemically synthesized siRNA, vector-based short hairpin RNAs (shRNAs) can be expressed intracellularly and effectively trigger long-lasting RNAi.[@bib15] At present, adeno-associated virus (AAV) has become the most widely applied vector to animal research and liver gene therapy because of the advantageous biological property of infecting a wide range of host cell types, such as liver.[@bib15]

This study aims to determine whether AAV-based shRNAs targeting FXII (AAV-shRNAs) exert considerable antithrombotic effect *in vivo*. Accordingly, our study demonstrated that FXII could be significantly reduced, and that selective knockdown of FXII prevented thrombus formation in arterial and venous thrombosis models without additional histologic lesion and hemorrhage.

Results {#sec2}
=======

Transfection Efficiency of AAV in Mouse Livers {#sec2.1}
----------------------------------------------

Previous studies proved that utilizing an adeno-associated virus serotype 8 (AAV8) vector can remarkably improve infection efficiency in mouse livers. Thus, we constructed an AAV8 vector expressing either *F12*-shRNAs (shRNA1 and shRNA2) or negative control (NC) shRNA (nc-shRNA) from a U6 promoter and ZsGreen reporter ([Figure S1](#mmc1){ref-type="supplementary-material"}). At 21 days after injection, the mouse livers were used to examine ZsGreen signals. [Figure 1](#fig1){ref-type="fig"}A shows that AAV8-treated livers exhibited highly efficient expression of ZsGreen, thereby indicating the superior transfection efficiency of AAV8.Figure 1Transfection Efficiency and Knockdown of *F12* in Livers(A) Images of mouse livers for detecting ZsGreen signals. (B) Mice were collected for quantification of hepatic FXII mRNA levels. (C) Protein levels of hepatic FXII were detected by immunoblot analysis. (D) FXII relative protein levels were quantified by densitometry. Error bars are SD (n = 3); ^ns^p \> 0.05, \*p \< 0.05, \*\*p \< 0.01.

Reduction of Hepatic FXII in mRNA and Protein Levels {#sec2.2}
----------------------------------------------------

In order to identify the interference effects of shRNAs, the livers were used to detect *F12* mRNA and protein levels. Quantitative real-time PCR data analyses revealed that the mRNA expression in the shRNA1 and shRNA2 groups decreased to 48% and 17% of the value in PBS-treated mice. No difference was found between nc-shRNA-treated and PBS-treated mice ([Figure 1](#fig1){ref-type="fig"}B), thereby confirming that the knockdown of *F12* was caused by shRNAs and not AAV8. In addition, we simultaneously tested the change of *F7*, which was important in thrombosis and bleeding. The results presented that shRNAs did not alter the *F7* ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We then determined whether the protein has the same changes in shRNAs-treated mice. [Figures 1](#fig1){ref-type="fig"}C and 1D show that the protein expression in the shRNA1 and shRNA2 groups were reduced by 18% and 48% compared with that in PBS-treated mice. Hence shRNAs could significantly decrease FXII, especially shRNA2.

Comparison of Coagulation Function in Plasmas {#sec2.3}
---------------------------------------------

To determine the influences of the coagulation function, we collected mouse plasmas for further experiments. The western blot results showed remarkable difference in FXII between the shRNA2-treated group (declined to 40%) and the shRNA1-treated group (reduced to 72%) ([Figures 2](#fig2){ref-type="fig"}A and 2B). These results are consistent with FXII activity in the shRNA1, shRNA2, nc-shRNA, and PBS groups, with values of 0.48 ± 0.12, 0.22 ± 0.07, 0.85 ± 0.19, and 1.00 ± 0.19, respectively ([Figure 2](#fig2){ref-type="fig"}C). As shown in [Figure 2](#fig2){ref-type="fig"}D, the *ex vivo* activated partial thromboplastin time (APTT) in the shRNA1 group remained the same level (22.13 ± 3.70 s) as that of the control, inconsistent with the results of plasma FXII antigen and activity. Moreover, shRNA2-treated mice (36.30 ± 1.84 s) displayed significant prolonged APTT compared with that in the nc-shRNA (20.87 ± 1.82 s) and PBS (19.67 ± 1.38 s) groups. We also detected prothrombin time (PT) and other coagulation activities of the intrinsic pathway, which were not different among the groups ([Figure S2](#mmc1){ref-type="supplementary-material"}B). By combining the results of APTT, PT, and intrinsic pathway factors, we identified that AAV-shRNAs specifically inhibited FXII without causing other changes.Figure 2Comparison of Coagulation Function in Plasmas between AAV- and PBS-Treated Groups(A) Immunoblots for plasma FXII; Ponceau staining served as the loading control. (B) Quantification of FXII relative protein levels. (C) Plasma FXII activity evaluated through clotting assays. The data were presented as percentage of pooled normal mouse plasma FXII activity. (D) *Ex vivo* APTT was quantified by clotting assays. Error bars are SD (n = 3); ^ns^p \> 0.05, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

AAV-shRNA-Mediated Anti-thrombosis Effects on FeCl~3~-Induced Carotid Artery Thrombosis {#sec2.4}
---------------------------------------------------------------------------------------

To evaluate the effects of shRNAs on thrombosis, we observed the blood vessels by H&E staining in FeCl~3~-induced carotid arterial thrombosis models ([Figure 3](#fig3){ref-type="fig"}). In our study, we did not observe any thrombus in the shRNA2-treated group ([Figure 3](#fig3){ref-type="fig"}C), whereas the shRNA1 group produced remarkable obstruction similar to PBS and NC groups ([Figures 3](#fig3){ref-type="fig"}A, 3B, and 3D). Furthermore, immunofluorescence results demonstrated the deposition of fibrin in the vessels. Hence only shRNA2 could effectively inhibit carotid artery thrombosis in FeCl~3~-induced models.Figure 3Effects on Arterial Thrombosis Induced by FeCl~3~Thrombus harvested from the carotid artery of (A) PBS-treated, (B) shRNA1-treated, (C) shRNA2-treated, and (D) nc-shRNA-treated mice. Thrombi were sectioned and subjected to immunofluorescence analysis using antibodies against fibrin or were stained with H&E.

AAV-shRNA-Mediated Anti-thrombosis Effects on FeCl~3~-Induced IVC Thrombosis {#sec2.5}
----------------------------------------------------------------------------

Exposure of inferior vena cava (IVC) to FeCl~3~ would cause endothelial damage, activate platelets, and trigger the intrinsic and extrinsic pathways of coagulation, ultimately leading to thrombus formation. Based on previous studies, *PF4* and *PECAM-1*[@bib16] were often elevated remarkably along with thrombosis. Thus, *PF4* and *PECAM-1* could contribute to estimation of clot sizes.[@bib17] qPCR data analyses demonstrated that the *PF4* expression was low in shRNA1 (0.04 ± 0.02) and shRNA2 (0.05 ± 0.01) groups ([Figure 4](#fig4){ref-type="fig"}A). However, differences exist in *PECAM-1* ([Figure 4](#fig4){ref-type="fig"}B), wherein only shRNA2 produced a remarkable reduction (0.41 ± 0.04), and shRNA1 presented no statistical difference (0.66 ± 0.33; p \> 0.05). By combining the results of *PF4* and *PECAM-1*, we could conclude that shRNA2 effectively restrained FeCl~3~-induced IVC occlusion.Figure 4Effects of shRNAs on Inferior Vena Cava Thrombosis Induced by FeCl~3~ and Stenosis(A and B) Thrombosis was induced by 10% FeCl~3~ solution and assessed using RT-PCR measurement of (A) *PF4* or (B) *PECAM-1* mRNA levels at the site of the IVC. (C) Thrombosis in stenosis-induced IVC among different treatment groups. IVC was obtained and stained with H&E after 24 h of vascular ligation. The red arrows indicate thrombi. Error bars are SD (n = 3); ^ns^p \> 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

AAV-shRNA-Mediated Anti-thrombosis Effects on Stenosis-Induced IVC Thrombosis {#sec2.6}
-----------------------------------------------------------------------------

To further assess the protective effect of shRNAs in thrombosis, we used partial IVC ligation for reducing the blood flow and producing minor endothelial damage that could induce IVC thrombosis. In this study, thromboembolism did not occur in shRNA2-treated mice ([Figure 4](#fig4){ref-type="fig"}C). By contrast, injection of shRNA1 did not inhibit thrombosis on stenosis-induced IVC thrombosis, as well as in PBS- and NC-treated groups.

Effects of AAV-shRNA2 Treatment on Hemostasis {#sec2.7}
---------------------------------------------

To determine whether shRNA2 mediated by AAV would increase hemorrhage risk, we estimated bleeding risk by bleeding time and blood loss through tail-bleeding assay ([Figures 5](#fig5){ref-type="fig"}A and 5B). The shRNA2 group exhibited no difference in blood loss and bleeding time compared with the PBS group (time: 24.2 ± 6.6 min and 38.7 ± 8.5 min for shRNA2- and PBS-treated groups, respectively). However, the mice injected with heparin showed prolonged bleeding time (\>90 min) and blood loss (absorbance of lost hemoglobin, 2.69 ± 0.03).Figure 5Effects on Hemostasis and Organic Pathology Caused by *F12*-shRNA2(A and B) Comparison of hemostasis between PBS- and shRNA2-treated groups assessed by (A) bleeding time and (B) blood loss. (C--F) Histologic sections of (C) liver, (D) brain, (E) kidney, and (F) heart stained with H&E and observed by 10× or 40× field.

Effects of AAV-shRNA2 Treatment on Biochemical Indicators and Histopathology {#sec2.8}
----------------------------------------------------------------------------

To further identify the side effects of AAV-shRNA2, we tested the plasma biochemical indicators, including alanine transaminase (ALT), creatinine (Cr), and creatine kinase (CK) ([Figure S4](#mmc1){ref-type="supplementary-material"}). No difference was found between the shRNA2-treated and control groups. In addition, histological sections of the liver, brain, kidney, and heart showed that AAV-shRNA2 had no remarkable toxicity to organs ([Figures 5](#fig5){ref-type="fig"}C--5F).

Discussion {#sec3}
==========

Based on clinical and animal studies, FXII plays a crucial role in pathologic coagulation. Animal experiments demonstrated that depletion of FXII significantly inhibited thrombus formation and prevented the eventual occurrence of cardiovascular and cerebrovascular diseases without bleeding risk.[@bib18] Accordingly, the proposed targeting FXII could be considered a safe anticoagulation profile. Anti-FXII drugs, such as antibodies, recombinant human albumin-infestin-4 (rHA-infestin-4), and antisense oligonucleotide, require repeated injections to induce anti-thrombosis effects or sustain only short-term effects, thereby restricting their application.

AAV-based shRNA has been widely used for gene interference. In this regard, we aim to determine whether the role of *F12*-shRNA mediated by AAV is crucial in anti-FXII and thromboembolism. In the present study, AAV8 exhibited high infection ability to liver, thereby ensuring the effective expression of shRNA to perform its function. The two shRNAs designed could reduce FXII mRNA expression and protein translation in livers. Furthermore, shRNA2 demonstrated increased inhibition capability. This conclusion could also be [drawn]{.ul} from testing the antigen and activity of FXII in plasma. However, we found no significant difference in APTT between the shRNA1 (22.1 s) and PBS groups; meanwhile, shRNA2 could prolong the APTT (36.3 s). APTT is widely used to assess hemostasis and monitor anticoagulant therapy.[@bib19], [@bib20] Thus, we could preliminarily estimate the antithrombotic effects. The results suggested that shRNA1 lacked sufficient ability to inhibit thrombosis.

Accordingly, we first observed whether a significant difference exists in the mouse carotid artery thrombosis to further study their function.[@bib3] Thrombus was formed in the common carotid artery in shRNA1, PBS, and NC groups, but the opposite result was detected in shRNA2-treated mice. Hence shRNA2, and not shRNA1, possessed sufficient capability for antithrombosis.

The expression levels of *PF4* and *PECAM-1* generally increase with thrombus formatting. Thus, the mRNA levels of *PF4* and *PECAM-1* could be considered a biomarker to assess thrombogenesis. In our experiments, the *PF4* mRNA expression decreased in the shRNA-treated FeCl~3~-induced IVC thrombosis model, whereas the expression of *PECAM-1* showed significant difference in the shRNA2 group only. We speculated that the discrepancy between *PF4* and *PECAM-1* was due to their sensibility. Although shRNA1 could not inhibit thrombosis, it can change *PF4.* We concluded that shRNA2 considerably delayed the occurrence of vein thrombus. Subsequently, the IVC thrombosis induced by stenosis was applied to evaluate anticoagulants to DVT.[@bib21] In this study, shRNA2, but not shRNA1, presented a remarkable anti-thrombosis effect on DVT, similar to the results of previous experiments.

Several factors should be carefully considered to evaluate whether this approach would be suitable for clinical evaluation. Hence we compared bleeding time and blood loss between shRNA2 and PBS groups. As predicted, shRNA2 targeting *F12* did not increase the hemorrhage risk. Based on the analysis of histological sections and biochemical indices, AAV-based shRNA did not influence the vital signs, and thus could be suitable for application.

In summary, AAV-based shRNA can be considered an effective method for treating or preventing thromboembolic diseases.

Materials and Methods {#sec4}
=====================

Design of *F12*-shRNA and AAV Vector Production {#sec4.1}
-----------------------------------------------

*F12*-shRNAs (GenBank: [NM_021489.3](ncbi-n:NM_021489.3){#intref0010}) were designed by Invitrogen's RNAi Designer (<http://rnaidesigner.thermofisher.com/rnaiexpress/>). The sequences of the shRNA1 and shRNA2 are shown in [Table S1](#mmc1){ref-type="supplementary-material"}. The structures of AAV8-U6-*F12*-shRNA1-CMV-ZsGreen, AAV8-U6-*F12*-shRNA2-CMV-ZsGreen, and AAV8-CMV-ZsGreen are shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. Vectors were constructed by HanBio Technology (Shanghai, China). The vector titers were checked by DNA dot blot method and were approximately 1.5 × 10^12^ viral particles per milliliter.

Mice and AAV Administration {#sec4.2}
---------------------------

Eight-week-old male C57BL/6 mice were provided by Shanghai SLAC Laboratory (Shanghai, China). The mice were housed in standard cages and handled according to institutional guidelines approved by the Animal Welfare and Use Committee of the Committee on the Ethics of Animal Experiments of the Wenzhou Medical University. The mice were injected with AAV-shRNA1, AAV-shRNA2, and AAV-nc-shRNA (0.8 × 10^10^ viral particles/g) by tail vein. PBS-treated mice were administered with the same volume of PBS. The mice were used in several tests with different treatments after 21 days.

Liver Fluorescence Detection {#sec4.3}
----------------------------

Liver sections were obtained, embedded in optimal cutting temperature compound (OCT), and frozen. Subsequently, 10-μm-thick sections were obtained by cryostat. Fluorescence was viewed in an inverted fluorescent micro6scope.

qPCR Analysis of F12 and F7 mRNA in Livers {#sec4.4}
------------------------------------------

Total mRNA was isolated from mouse livers by using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) chloroform method. cDNA was synthesized with HiScript Q RT SuperMix (Vazyme Biotech, Nanjing, China). Real-time PCR was performed on Applied Biosystem 7900 (Applied Biosystems, Foster City, CA, USA) with Sybrgreen (Vazyme Biotech, Nanjing, China). The gene and primer sequences are provided in [Table S2](#mmc1){ref-type="supplementary-material"}. Experiment for qPCR was performed in triplicate, and the results were analyzed using the comparative (ΔΔCt) method.

Western Blot Analysis {#sec4.5}
---------------------

Western blot was performed following the standard protocol to analyze FXII expression in the liver and plasma. GAPDH was detected with mouse anti-GAPDH antibody (cat. no. 60004-1-Ig; Proteintech Group, Chicago, IL, USA). FXII was detected with mouse anti-FXII antibody (cat. no. 66089-1-Ig; Proteintech Group, Chicago, IL, USA). Goat anti-mouse IgG (H+L) (cat. no. 925-68070; LI-COR Biosciences, Lincoln, NE, USA) was used as secondary antibody. The blots were imaged by Odyssey Imager (LI-COR Biosciences, Lincoln, NE, USA). Plasma proteins were stained by Ponceau S (cat. no. P0022; Beyotime, Shanghai, China) for internal reference.

Coagulation Function Detection {#sec4.6}
------------------------------

Blood was collected via carotid artery cannulas and mixed with 0.109 M sodium citrate. Plasma was prepared by centrifugation at 4,000 × *g* for 10 min to remove cellular elements. The activities of factors, APTT, and PT were detected using an automation coagulator STA-R Evolution (Stago, NJ, USA) following the standard protocol.

Arterial Thrombosis Assays {#sec4.7}
--------------------------

Thrombosis was induced by FeCl~3~ through a previously reported method.[@bib22], [@bib23] A single 1 × 2 mm strip of Whatman filter paper was soaked in a solution of 10% FeCl~3~ and applied to the adventitial surface of the carotid artery. After 3 min, the paper was removed, and the vessel was washed by PBS. After another 15 min, the injured vessel was embedded in OCT and cut into 10-μm sections for H&E or immunofluorescence staining. Fibrin was detected with anti-mouse fibrin IgG (cat. no. 66158-1-Ig; Proteintech Group, Chicago, IL, USA) and visualized with secondary anti-mouse Alexa Fluor 555 IgG (cat. no. A0460; Beyotime, Shanghai, China). The slides were rinsed with PBS. The coverslips were mounted with DAPI dihydrochloride (cat. no. D9542; Sigma-Aldrich, Saint Louis, MO, USA) and visualized using an LSM 880 microscope (Zeiss, Oberkochen, Germany).

Ferric Chloride-Induced IVC Thrombosis {#sec4.8}
--------------------------------------

IVC was exposed and separated from the abdomen. The process of inducing IVC thrombosis was similar to that for arterial thrombosis.[@bib14] The injury fragment was used for mRNA extraction and detection of PF4 and PECAM-1 expression, and the process was performed following the standard protocol. The sequences of genes and primers are shown in [Table S2](#mmc1){ref-type="supplementary-material"}.

Stenosis-Induced IVC Thrombosis {#sec4.9}
-------------------------------

A 6-0 silk tie was placed behind the vessel, and a metal 4-0 suture was placed longitudinally over the IVC and tied over the top. The metal suture was removed, and two neurovascular surgical clips were applied at two separate positions below the ligation for 20 s. The bowel was replaced into the abdominal cavity, and the abdomen was closed. After 24 h, IVC was collected and fixed in 4% paraformaldehyde for H&E staining for 24 h.

Tail-Bleeding Assay {#sec4.10}
-------------------

Bleeding times were determined using a previously described method.[@bib24] The mice were anaesthetized and injected intravenously with PBS buffer. Mice in the heparin group were injected with 200 U/kg heparin. After 10 min, the mouse tails were transected 3 mm from the tip. The bleeding tail was immersed in a 15-mL test tube containing 12 mL of pre-warmed PBS. Bleeding time was recorded from the time of transection to the cessation of bleeding for 10 s. Blood loss was quantified by measuring the hemoglobin content of blood collected into PBS. After centrifugation, the pellet was lysed with lysis buffer (8.3 g/L NH4Cl, 1.0 g/L KHCO3, and 0.037 g/L EDTA). The absorbance of the sample was recorded at 575 nm. The experiment was continued until the bleeding stopped completely or at 90 min.

Biochemistry Indicator Assay and Histopathological Detection {#sec4.11}
------------------------------------------------------------

Plasmas from shRNA2- and PBS-treated mice were collected to test ALT, Cr, and CK on VITROS@ 5600 (Ortho Clinical Diagnostics, Raritan, NJ, USA). Standard techniques for H&E staining were performed on the brains, kidneys, livers, and hearts to identify the toxic reaction on the organs.
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